Back to Annual Meeting

Back to Annual Meeting

Abstract #150419

• Slides (pdf) or Handout

Rodney G. Bowden, PhD¹, Ronald L. Wilson, MD², Mindy Gentile, MS, RD, LD³, Songthip T. Ounpraseuth, PhD⁴, and Page Moore, PhD⁴. (1) Hhpr, Baylor University, One Bear Place #97304, Waco, TX 76798-7304, 254-710-4499, Rodney_Bowden@baylor.edu, (2) Central Texas Nephrology Associates, 213 Ivy, Waco, TX 76798, (3) Brazos Kidney Center, 213 Ivy, Waco, TX 76798, (4) Biostatistics, University of Arkansas for Medical Sciences, 4301 W. Markham St., Slot 781, Little Rock, AR 72205-7199

Introduction: Thromboses are more likely to occur with End-Stage Renal Disease patients in their vascular access which can cause increased morbidity and mortality. Objective: The purpose of this study was to investigate the effects of orally administered over-the-counter (OTC) n-3 fatty acid supplements on primary patency of polytetrafluorethylene (PTFE) grafts. Design: The study was conducted using a triple-blind, permuted-block randomized and placebo controlled experimental design. Central Texas Nephrology Associates related dialysis clinics with patients who needed a new PTFE graft based on physician diagnosis were recruited for the study. Patients (N=34) were followed prospectively for 8-months after being placed into an n-3 fatty acid or control group and monitored for primary patency as the primary outcome variable. Primary patency is defined as patients having avoided either a placement of a new graft or angioplasty due to a thrombosis in the vascular access of the draining vein. Results: The n-3 fatty acid group had a mean PTFE graft primary patency rate of 254.2 days (SEM=51.8), while the control group had a mean PTFE graft primary patency rate of 254.1 days (SEM=34.6) revealing no significant difference in survival time between groups [Log-Rank (.7451), Wilcoxon (.4221) and -2Log (LR) (.5883)] using Kaplan-Meier and Cox proportional hazard method. There were no significant differences in the covariates with the exception of small LDL. Conclusions: There were no significant differences in primary patency rates between groups suggesting the OTC supplement may have not had enough DHA and EPA to elicit a response of decreased endothelial hyperplasia.

Learning Objectives:

• Participants will learn the importance of the dose-response relationship with omega-3 fatty acid consumption
• Participants will learn about disease progression with End-Stage Renal Disease
• Participants will understand the health benefits associated with consumption of omega-3 fatty acids

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

• Slides (pdf) or Handout